Anti-aging effects of ingenol mebutate for patients with actinic keratosis
To the Editor: Ingenol mebutate (IM) gel has been approved by the Food and Drug Administration as a topical field-directed therapy for actinic keratosis (AK) and has been shown to cure subclinical and clinically apparent AKs. 1 Recently, there have been reports of improvements in skin elasticity, wrinkles, and mottled pigmentation after the application of IM gel in patients with multiple AK lesions. 2, 3 In this study, we aimed to investigate histologic and molecular alterations after field cancerization by using topical IM gel in patients with multiple AK lesions and elucidate the mechanism underlying the skinrejuvenating effect of IM gel.
A total of 19 patients (11 women and 8 men; mean age, 73.2 6 11.9 years; Fitzpatrick skin type IIIeIV) with multiple histologically confirmed AK lesions on their faces were enrolled in this study. The study was approved by the Institutional Review Board of the Catholic University of Korea. IM gel (0.015% gel, Picato; LEO Pharma, Ballerup, Denmark) was applied to the entire AK lesions on the face once daily for 3 days in a row, 1 tube/day. We instructed the patients to avoid the sun and actively use sunscreen and to apply cold gauze when they felt a burning sensation. Blisters and erythema occurred in 3 patients on the applied area, but blisters and erythema improved within a few days. Two independent dermatologists evaluated the overall appearance, pigmentation, wrinkles, and texture of the skin on the basis of a 5-point scale: no improvement, \25% improvement, 25%-50% improvement, 51%-75% improvement, and [75% improvement. All 19 patients showed [50% improvement in pigmentation, and 92% showed [50% improvement in wrinkles and skin texture (Fig 1, A) .
Skin samples obtained at baseline and 8 weeks after treatment with IM gel were sectioned and hematoxylin-eosin stained or Masson trichrome stained. The amount of collagen increased throughout the dermis and solar elastosis was reduced; elastin fibers in baseline skin samples acquired before treatment appeared to be replaced by thickened collagen bundles in skin samples acquired after treatment (Fig 1, B and C ) . In addition, we extracted RNA from formalin-fixed paraffinembedded skin samples acquired before and after treatment to determine the dynamic molecular changes. Type I collagen and transforming growth factor (TGF-) mRNA expression levels were significantly increased, and matrix metalloproteinase 1 mRNA expression was significantly decreased in skin samples acquired after treatment compared with those acquired before treatment (P \ .05) (Fig 2) .
IM gel has both cytotoxic and immunomodulatory effects; the gel can induce apoptosis of transformed keratinocytes and inflammatory reactions that eliminate precancerous lesions. 4 Our histologic and molecular data demonstrated that type I collagen and TGF-were significantly increased in the posttreatment skin compared with the pretreatment skin. TGF-is the most potent cytokine for wound healing through stimulation of dermal collagen remodeling. 5 IM gel probably stimulates cytokine secretion in several inflammatory cells in the dermis, which might increase TGF-and stimulate collagen production, resulting in skin rejuvenation. This study indicates that IM gel has a rejuvenating effect on photodamaged skin with multiple AK lesions by providing a deeper 
Minimal clinically important differences for measures of treatment efficacy in StevensJohnson syndrome and toxic epidermal necrolysis
To the Editor: There is a lack of evidence for benefit of any specific treatment for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). 1 The purpose of this study was to survey North American dermatologists and burn surgeons to estimate the minimally clinical important difference (MCID) in key outcomes for assessing treatment efficacy in SJS and TEN. MCID provides a measure of the smallest change in a specific treatment outcome that clinicians perceive as important and practice-changing. MCID are needed to effectively evaluate treatment efficacy in a clinically meaningful way for physicians. Establishing the MCID is the first step in designing rigorous randomized controlled trials to evaluate treatments for SJS and TEN. There is a lack of clinical trials for these life-threatening conditions, and this study lays the essential groundwork for future trial design.
A survey was designed to estimate MCID values for a) length of time to achieve full reepithelialization (complete healing), b) length of time before cessation of disease progression, c) length of hospital stay, and 4) rate of mortality. This confidential and anonymous survey (constructed using SurveyMonkey, San Mateo, California) was electronically disseminated to a total of 928 dermatologists and burn surgeons who specialize in SJS and TEN care across North America. Participants were identified through 
